Literature DB >> 20421784

Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.

Sujata Narayanan1, Kristina Callis-Duffin, Julia Batten, Neeraj Agarwal.   

Abstract

Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20421784     DOI： 10.1097/MAJ.0b013e3181dd1aa5

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN： 0002-9629            Impact factor:   2.378


  8 in total

Review 1.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 2.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

3.  Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.

Authors:  A V Mezentsev; S A Bruskin; A G Soboleva; V V Sobolev; E S Piruzian
Journal:  Int J Biomed Sci       Date:  2013-09

4.  IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.

Authors:  Charlie Bridgewood; Gareth W Fearnley; Anna Berekmeri; Philip Laws; Tom Macleod; Sreenivasan Ponnambalam; Martin Stacey; Anne Graham; Miriam Wittmann
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

5.  Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease.

Authors:  Farida Benhadou; Elisabeth Glitzner; Audrey Brisebarre; Benjamin Swedlund; Yura Song; Christine Dubois; Milena Rozzi; Catherine Paulissen; Veronique Del Marmol; Maria Sibilia; Cédric Blanpain
Journal:  Sci Adv       Date:  2020-01-08       Impact factor: 14.136

Review 6.  Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis.

Authors:  Anja K Weidemann; Ania A Crawshaw; Emily Byrne; Helen S Young
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-09-26

7.  In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy.

Authors:  Jing Li; Nan Zhou; Kun Luo; Wei Zhang; Xinru Li; Chuanfang Wu; Jinku Bao
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

Review 8.  Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.

Authors:  Andrea Luengas-Martinez; Ralf Paus; Helen S Young
Journal:  Br J Dermatol       Date:  2022-03-17       Impact factor: 11.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.